Ex-Pfizer sales exec fined $75,000 in Bextra off-label case
This article was originally published in Scrip
Executive Summary
A former Pfizer regional sales manager, Mary Holloway, has been sentenced for off-label marketing of the COX-2 inhibitor, Bextra (valdecoxib), a violation of the FD&C Act, according to the US Attorney's Office for the District of Massachusetts. Sales of the product were suspended globally in April 2005 by Pfizer, which had gained it through its acquisition of Pharmacia.